網膜静脈分枝閉塞症に伴う黄斑浮腫に対するラニビズマブ投与の短期成績

Short-term outcome of intravitreal injection of ranibizumab for macular edema in branch retinal vein occlusion

要約　目的：網膜静脈分枝閉塞症（BRVO）に伴う黄斑浮腫に対するラニビズマブ硝子体注射の短期成績の報告。

対象と方法：BRVOに伴う黄斑浮腫に対し，初診時の視力にかかわらず，ラニビズマブ硝子体注射を行い，6か月以上の観察ができた33例33眼を対象とした。男性17例，女性16例で，年齢は55〜86歳，平均72歳であった。矯正視力，中心網膜厚，黄斑浮腫の再発とその回数，ラニビズマブ投与回数を検討した。視力はlogMARとして評価した。

結果：視力は治療前0.37±0.05，最終観察時0.1±0.05で，有意に改善した。中心網膜厚は治療前529±31.75μm，最終観察時274.5±18.0μmで，有意に減少した。黄斑浮腫の再発と治療前視力に正の相関があり，黄斑浮腫が軽快した症例では，治療前視力が良好であるほど寛解までの期間が短く，ラニビズマブの投与回数が少なかった。

結論：BRVOに伴う黄斑浮腫に対するラニビズマブ硝子体注射により，6か月以降の視力が改善し，中心網膜厚が減少した。

Abstract　Purpose：To report the short-term outcome of intravitreal injection of ranibizumab for macular edema in branch retinal vein occlusion（BRVO）.

Cases and Method：This retrospective study was made on 33 eyes of 33 patients who received intravitreal injection of ranibizumab for macular edema in BRVO and who were followed up for 6 months or longer. The series comprised 17 males and 16 females. The age ranged from 55 to 86 years, average 72 years. Outcome of treatment was evaluated regarding visual acuity, central retinal thickness, recurrence of macular edema, and number of sessions of ranibizumab treatment. Visual acuity was evaluated as logMAR.

Results：Visual acuity averaged 0.37±0.05 before treatment and 0.1±0.05 at the final observation. The difference was significant. Central retinal thickness averaged 529±31.75 μm before treatment and 274.5±18.0 μm at the final observation. The difference was significant. There was a positive correlation between rate of recurrence and initial visual acuity. Cases of favorable outcome showed lesser number of ranibizumab sessions. Duration between occurrence and cure was shorter in cases with better initial visual acuity.

Conclusion：Intravitreal ranibizumab injection resulted in better visual acuity and decrease in central retinal thickness following intravitreal ranibizumab injection for macular edema in BRVO.